Turn Therapeutics Inc.

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices.

Current securities

1. Regulation FD DisclosureSep 10, 2026
2. Regulation FD DisclosureSep 9, 2026
3. D filingAug 26, 2026
4. Unregistered Sales of Equity SecuritiesAug 18, 2026
5. Regulation FD DisclosureAug 17, 2026